Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2003 Sep;74(9):1225–1230. doi: 10.1136/jnnp.74.9.1225

A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment

J Craig 1, C Young 1, M Ennis 1, G Baker 1, M Boggild 1
PMCID: PMC1738635  PMID: 12933923

Abstract

Background: There is evidence to support both the use of intravenous methylprednisolone (IVMP) in multiple sclerosis (MS) relapse and physiotherapy in the management of MS, but no studies have investigated the combination of steroids and rehabilitation together.

Objectives: To evaluate the benefits of IVMP with planned, comprehensive multidisciplinary team (MDT) care compared to IVMP with standard care.

Methods: In this randomised controlled trial, patients confirmed to have had a definite MS relapse severe enough to warrant IVMP (1 g daily for three days) were randomised to two groups. The control group was managed according to the standard ward routine; the treatment group received planned coordinated multidisciplinary team assessment and treatment. Baseline assessments, including demographics and Expanded Disability Status Scale (EDSS) were carried out on both groups. The primary outcome measures were Guy's Neurological Disability Scale (GNDS), and Amended Motor Club Assessment (AMCA). The secondary measures were the Barthel Index (BI), Human Activity Profile (HAP), and Short Form Item 36 Health Survey (SF-36). All measures have published data on reliability and validity. Measures were administered at one and three months.

Results: Forty subjects, including 27 females, completed data collection. There were no significant differences between the two groups at baseline. Results showed statistically significant differences in GNDS (p = 0.03), AMCA (p = 0.03), HAPM (p < 0.01), HAPA (p = 0.02), and BI (p = 0.02) at three months in favour of planned MDT care.

Conclusion: This study indicates that combining steroids with planned MDT care is superior to administering them in a standard neurology or day ward setting. Further research is necessary in order to confirm this finding.

Full Text

The Full Text of this article is available as a PDF (124.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes D., Hughes R. A., Morris R. W., Wade-Jones O., Brown P., Britton T., Francis D. A., Perkin G. D., Rudge P., Swash M. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet. 1997 Mar 29;349(9056):902–906. doi: 10.1016/s0140-6736(96)06453-7. [DOI] [PubMed] [Google Scholar]
  2. Bethoux F., Miller D. M., Kinkel R. P. Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life. Mult Scler. 2001 Apr;7(2):137–142. doi: 10.1177/135245850100700210. [DOI] [PubMed] [Google Scholar]
  3. Collin C., Wade D. T., Davies S., Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud. 1988;10(2):61–63. doi: 10.3109/09638288809164103. [DOI] [PubMed] [Google Scholar]
  4. Daughton D. M., Fix A. J., Kass I., Bell C. W., Patil K. D. Maximum oxygen consumption and the ADAPT quality-of-life scale. Arch Phys Med Rehabil. 1982 Dec;63(12):620–622. [PubMed] [Google Scholar]
  5. De Souza L. H., Ashburn A. Assessment of motor function in people with multiple sclerosis. Physiother Res Int. 1996;1(2):98–111. doi: 10.1002/pri.6120010206. [DOI] [PubMed] [Google Scholar]
  6. Freeman J. A., Hobart J. C., Langdon D. W., Thompson A. J. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):150–156. doi: 10.1136/jnnp.68.2.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Freeman J. A., Langdon D. W., Hobart J. C., Thompson A. J. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology. 1999 Jan 1;52(1):50–56. doi: 10.1212/wnl.52.1.50. [DOI] [PubMed] [Google Scholar]
  8. Freeman J. A., Langdon D. W., Hobart J. C., Thompson A. J. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol. 1997 Aug;42(2):236–244. doi: 10.1002/ana.410420216. [DOI] [PubMed] [Google Scholar]
  9. Goodkin D. E. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. West J Med. 1994 Sep;161(3):292–298. [PMC free article] [PubMed] [Google Scholar]
  10. Hoogervorst E. L., Kalkers N. F., van Winsen LML, Uitdehaag B. M., Polman C. H. Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis. Mult Scler. 2001 Oct;7(5):335–339. doi: 10.1177/135245850100700510. [DOI] [PubMed] [Google Scholar]
  11. Kidd D., Thompson A. J. Prospective study of neurorehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):423–424. doi: 10.1136/jnnp.62.4.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lord S. E., Wade D. T., Halligan P. W. A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study. Clin Rehabil. 1998 Dec;12(6):477–486. doi: 10.1191/026921598675863454. [DOI] [PubMed] [Google Scholar]
  13. Lublin F. D., Reingold S. C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 Apr;46(4):907–911. doi: 10.1212/wnl.46.4.907. [DOI] [PubMed] [Google Scholar]
  14. Mertin J. Rehabilitation in multiple sclerosis. Ann Neurol. 1994;36 (Suppl):S130–S133. doi: 10.1002/ana.410360731. [DOI] [PubMed] [Google Scholar]
  15. Miller C. M., Hens M. Multiple sclerosis: a literature review. J Neurosci Nurs. 1993 Jun;25(3):174–179. doi: 10.1097/01376517-199306000-00007. [DOI] [PubMed] [Google Scholar]
  16. Sharrack B., Hughes R. A. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler. 1999 Aug;5(4):223–233. doi: 10.1177/135245859900500406. [DOI] [PubMed] [Google Scholar]
  17. Stevenson V. L., Thompson A. J. The management of multiple sclerosis: current and future therapies. Drugs Today (Barc) 1998 Mar;34(3):267–282. doi: 10.1358/dot.1998.34.3.485182. [DOI] [PubMed] [Google Scholar]
  18. Tremlett H. L., Luscombe D. K., Wiles C. M. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry. 1998 Sep;65(3):362–365. doi: 10.1136/jnnp.65.3.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ware J. E., Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed] [Google Scholar]
  20. Wiles C. M., Newcombe R. G., Fuller K. J., Shaw S., Furnival-Doran J., Pickersgill T. P., Morgan A. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):174–179. doi: 10.1136/jnnp.70.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES